A randomized trial evaluating the effect of exemestane in clinical stage T1-3 N0-1 M0 postmenopausal breast cancer patients completing at least five years of tamoxifen therapy.

Trial Profile

A randomized trial evaluating the effect of exemestane in clinical stage T1-3 N0-1 M0 postmenopausal breast cancer patients completing at least five years of tamoxifen therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2014

At a glance

  • Drugs Exemestane (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2011 The ClinicalTrials.gov record reports the completion date as 18 Apr 2011.
    • 16 Mar 2011 National Cancer Institute of Canada reports actual initiation date as 3 Jun 2002 and actual end date 9 Oct 2003.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top